Efficacy of platelet rich plasma injection in diabetic neuropathy: double blinded randomized controlled trial
Notice bibliographique
Résumé
Background: Neuropathy is a common complication of diabetes mellitus (DM) with a wide clinical spectrum that encompasses generalized to focal and multifocal forms not only leads to an impaired quality of life, but also to an increased morbidity and mortality . Till now there is no available effective therapy for the treatment of diabetic peripheral neuropathy (DPN). Autologous platelet-rich plasma is easy and cost-effective method as it provides necessary growth factors that promote wound healing/growth, angiogenesis, and axon regeneration .Objective: To evaluate the clinical efficacy and safety of peri-neural injection of platelet rich plasma (PRP) in the treatment of diabetic peripheral neuropathy compared to traditional medical treatment.Method : Prospective double blinded randomized controlled trial was conducted (ClinicalTrials.gov Identifier: NCT03250403) . All included patients had type 2 DM selected from Endocrinology unit Department of Internal medicine, Assuit university Hospital, Egypt . DPN of at least 5 years duration of symptoms . Patients with other causes of neuropathy like hereditary neuropathies , entrapment neuropathies , overt neuropathy with foot ulcers and /or amputation , peripheral arterial diseases ,connective tissue diseases , vertebral diseases ,thyroid disorders and end organ failure were excluded . Neuropathy was assessed by the modified Toronto Clinical Neuropathy Score (mTCNS) 2009 (3) Symptom scorestSensory test scoresFoot paintPinprickNumbnesstTemperatureTinglingtLight touchWeaknesstVibrationAtaxiatPosition SenseUpper limb symptomsSymptom scores graded astSensory test scores graded as0 = absentt0 = normal1 = present but no interference with sense of well-being or activities of daily livingt1 = reduced at the toes only2 = present, interferes with sense of well-being but not with activities of daily livingt2 = reduced to a level above the toes, but only up to the ankles3 = present and interferes with both sense of well-being and activities of daily living (both)t3 = reduced to a level above the ankles and/or absent at the toes Baseline pain and nerve conduction studies were done. Regardless of age and gender participants were double blindly divided into two groups, both the control and experimental groups received primary treatment (vitamin B complex, u03b1 lipoic acid, SSRI) and strictly control blood glucose. Group I underwent PRP peri-neural injection under ultrasound guidance . Group u05f0received medical treatment only( control group) . Blood glucose was strictly controlled in both groups . Patients were followed every month for 3 months by mTCNS and by nerve conduction studies. Results were expressed as means u00b1 standard deviation or frequencies. Independent Studentu2019s t test and mann-whitney test were used for comparison between groupsResults: the study included 60 type 2 diabetic patients with peripheral neuropathy , 33(55%)were female with a mean age (u00b1 SD) of 35.27 u00b1 12.86 years with duration of DPN 7.42 u00b1 1.51 years . Of these, there was 34/60 (56%) cases with lower limb neuropathy only. while the rest (26/60) (44%) had both lower and upper limb nerves neuropathy, Nerve conduction study showed axonal affection in only 16/60 cases (26%) and 100% had delayed distal latency and prolonged motor conduction velocities.40 patients underwent PRP peri-neural injection. Significant symptomatic improvement in group I versus group u05f0 (P value u22640.001). both mean motor nerve conduction velocity of lower limb and Sural conduction velocity were accelerated in group I after 6 months of application of PRP (P value u22640.05, u22640.001 respectivly), also mTCNS had improved in group I post PRP injection 10.6u00b1 3.2 versus 21.3u00b1 5.4 at baseline (P value u22640.001).
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,004 | 0,004 |
| Méta-épidémiologie (sens strict) | 0,002 | 0,001 |
| Méta-épidémiologie (sens large) | 0,008 | 0,003 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,001 | 0,002 |
| Communication savante | 0,002 | 0,002 |
| Science ouverte | 0,001 | 0,001 |
| Intégrité de la recherche | 0,004 | 0,003 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,009 | 0,001 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».